SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Archemix Corp., a biotechnology company, engages in discovering, developing, and commercializing aptamer therapeutics for the prevention and treatment of chronic and acute diseases in Massachusetts. Its aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure. The company also offers product candidates for cardiovascular, hematology, and oncology diseases. Archemix Corp. was incorporated in 2000 and is based in Cambridge, Massachusetts.

RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. It utilizes the Ribomic Aptamer Therapeutics (RiboART) system to discover new drugs that are applicable to target proteins. The company was founded by Yoshikazu Nakamura on August 1, 2003 and is headquartered in Tokyo, Japan.

MeiraGTx UK II Ltd., a subsidiary of MeiraGTx Holdings Plc, is a company headquartered in London, UK. The firm develops novel gene-based therapies for retinal disorders that lead to vision loss. It was founded in 2014.

Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline includes several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration is the first such trial for an siRNA drug.

Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France.

NEC Soft provides information technology products and services that match the changes in the business environment and the level of customer growth. The company's business includes creating IT-driven management strategies, system development, implementation and operation, and outsourcing services. NEC Soft was established in 1975 and is based in Tokyo, Japan, with several office locations around Japan.

Nexmos Co. Ltd. is a South Korean private company with domestic subsidiaries. The firm provides biotechnology and healthcare services.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

ICCAS was founded in 1956. ICCAS is a multi-disciplinary research institute dedicated to the basic research in broad fields of chemical sciences, and to the key developments of the innovative high technologies aiming to the imperative national needs and important strategic targets, as well as to the collaborative high-technology applications and transfers. ICCAS is one of China’s leading chemistry research institutions with high international reputation.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

TagCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. The Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.

Dongguk University Industry-Academic Cooperation Foundation is for the promotion of tenants and entrepreneurship.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Fujimoto Pharmaceutical is a manufacturing company that develops medical and therapeutic drugs. The company was founded in August 1933 and is based in Matsubara City, Osaka, Japan.